AVIR
Atea Pharmaceuticals, Inc.
A Boston drug developer that makes oral antiviral medicines for serious viral infections, with its lead program pairing bemnifosbuvir and ruzasvir against hepatitis C. It was founded in 2012 by Jean-Pierre Sommadossi, a co-founder of Pharmasset, the company behind the hepatitis C treatment sofosbuvir, sold as Sovaldi. Sommadossi helped build that earlier drug, and Atea carries forward the same nucleoside antiviral science.
CUSIP: 04683R106HealthcareUS1 holder
Total Value
$58.03M
Total Shares
1.66M
Net Share Change
+1.66M
Activity
1 buying
Investor
Value
Shares
Weight
Change
